Revvity Nitrendipine, -, 25uCi (925kBq)

Revvity Nitrendipine acts as an antagonist at dihydropyridine calcium channel blockers (CCB), and is used to treat primary hypertension. We offer both agonist and antagonist radioligands for autoradiographic visualization or performing saturation and competition assays to determine receptor expression levels (Bmax), dissociation constants (Kd), association and dissociation rates (kon and koff), and inhibitor constants (Ki) for a variety of receptors. We develop our radioligands to the highest specific activity possible and provide high purity resulting in low non-specific binding products. Each of our ultra-pure radioligands is fully characterized for pharmacological action and validated in receptor binding assays. Radiolabeled ligands remain the most sensitive method for probing receptor binding biology; yielding unprecedented sensitivity gives results that technicians and scientists can trust. For over 50 years, PerkinElmer has been a leading supplier of New England Nuclear (NEN) radiochemicals, liquid scintillation cocktails, vials and nuclear counting detection instruments. References for NET741: Schoemaker, H., (1992) Polyamines allosterically modulate [3H]nitrendipine binding to the voltage-sensitive calcium channel in rat brain, In European Journal of Pharmacology: Molecular Pharmacology, 225 (2): 167-169. Janis, R. A., Krol, g. J., Noe, A. J. and Pan, M. (1983), Radioreceptor and High-Performance Liquid Chromatographic Assays for the Calcium Channel Antagonist Nitrendipine in Serum. The Journal of Clinical Pharmacology, 23: 266-273. - PEMSD (Additional S&H or Hazmat Fees May Apply)